• CTI, Servier’s Pixuvri fails in post-marketing trial pharmatimes
    July 16, 2018
    A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche's MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy.
  • CTI BioPharma Appoints Director contractpharma
    July 25, 2017
    Dr. Fischer brings 20 years of experience in developing and commercializing biopharmaceuticals
PharmaSources Customer Service